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The BioEnterics Intragastric Balloon (BIB) and the Spatz Adjustable Balloon System (ABS) are in fact
recommended for weight reduction as a bridge to bariatric surgery. We retrospected studied patients
with body mass index (BMI) and age ranges of 37e46 and 70e80 years, respectively, who had undergone
BIB from January 2010 to July 2012 and prospected studied patients who had undergone Spatz balloon
from July 2012 to August 2014. The aim of this study is to compare BIB and Spatz in terms of weight loss,
complications, and maintenance of weight after removal. For both procedures, the median weight loss
was 20 ± 3 kg, median BMI at the end of the therapy was 32 ± 2, and no severe complication occurred.
© 2016 IJS Publishing Group Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
The BioEnterics Intragastric Balloon (BIB) and the Spatz
Adjustable Balloon System (ABS) are the most commonly used
devices for temporary treatment in obese patients. These systems
are in fact recommended for weight reduction as a bridge to bar-
iatric surgery [1e4]. The drawbacks of the BIB, such as the lack of
adjustability, short-term therapy (6 months), deﬂation, and bowel
obstruction, seem to be overcome by the Spatz balloon [2]. This is a
dynamic bariatric device with a long implantation time (12
months), system for inﬂation and deﬂation of the balloon, and
safety mechanism that precludes its bowel migration despite an
eventual deﬂation.2. Objective
The aim of this study was to compare BIB and Spatz in terms of
weight loss, complications, and maintenance of weight after
removal.so), giovanni.aprea@unina.it
ox@hotmail.it (S. Ruggiero),
ra@unicz.it (R. Serra),
unina.it (L. Sivero).
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From January 2010 to August 2014, 30 patients underwent im-
plantation of the two intragastric devices in our Department of
Digestive Endoscopy. We retrospectively studied patients who had
undergone BIB from January 2010 to July 2012 and prospectively
studied patients who had undergone Spatz balloon from July 2012
to August 2014. The patients were selected according to NIH criteria
[3e5]. The inclusion criteria were BMI 27e30, previous failure of
dietary measures, and the presence of one of the following
comorbidities: hypertension, diabetes, respiratory disorders,
osteoarthropathy, and dyslipidemia.
BIB was placed in 20 patients (7 male, 13 female; age range:
70e80 years, BMI range: 37e46; weight range: 103e165 kg).
Spatz balloon was placed in 10 patients (3 male, 7 female; age
range: 70e80 years; BMI range: 37e46; weight range: 103e165 kg).
All patients underwent EGDS before procedure. The complica-
tions of the procedure (deﬂation, rupture of stabilizer band, bowel
migration, gastric ulcer, gastrectasia, intolerance, nausea, and
vomiting) were pointed out in the informed consent during med-
ical interview [6e8]. All patients were hospitalized, fasted 12 h
before the procedure, and both devices were placed on patients in
the operating theater under unconscious sedation. Adjustment
procedure of Spatz was performed with the endoscopic in-
struments, extracting the ﬁlling tube. In this way, it was possible to
deﬂate (to resume the normal diet) and inﬂate the balloon withd.
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nonsigniﬁcant).
Patients of both groups received the same medical treatment, as
described in the medical literature [9].
On the ﬁrst postoperative day, intravenous saline (30e35ml/kg/
die) with omeprazole (40 mg/die), ondansetron (8 mg/die), and
butylscopolamine bromide (20 mg  3/die) were administered to
all patients.
On the second postoperative day, the patients were discharged
with drug therapy: omeprazole (40 mg/die) and a 1000-Kcal diet.
In this study, we evaluated the efﬁcacy of the procedure
considering:
- weight loss parameters after 6months (time of BIB removal) and
12 months (time of Spatz removal)
- maintenance of weight after removal
- short- and medium-term complications
- long-term complication for BIB.
These results were obtained by a medical interview for retro-
spective study of the BIB and with a 3- to 9-month follow-up of the
prospective study of Spatz balloon.4. Results
No complication occurred during the procedure and removal of
devices in either groups.
In two of 20 patients treated with BIB, the balloon was removed
due to intolerance (one patient) and gastrectasia (one patient). In
only one patient, the balloonwas removed for bowel migration, the
real complication of the procedure. In the remaining 17 patients,
the balloon was removed after 6 months at the end of the therapy.
In two of 10 patients treated with Spatz, the balloon was
removed due to vomiting. The adjustment procedure of Spatz was
performed in three patients. In the remaining ﬁve patients, the
balloon was removed after 10 months, the average time to the end
of the therapy.
For both procedures, median weight loss was 20 ± 3 kg and
median BMI at the end of the therapy was 32 ± 2.
At 3-month follow-up, weight gains were 4 ± 2 kg for eight
patients with Spatz and 3 ± 2 kg for 17 patients with BIB.
At 6-month follow-up, weight gains were 6 ± 2 kg for ﬁve pa-
tients with Spatz and 6 ± 1.5 kg for 10 patients with BIB.
At 9-month follow-up, weight gains were 10 kg for one patient
with Spatz and 11 ± 2 kg for three patients with BIB.
The two patients who underwent adjustment of Spatz balloon
did not achieve signiﬁcant weight loss.
At long-term follow-up, no complication occurred for BIB.5. Discussion
At present, endoscopic positioning of intragastric balloon has
been proved as an effective procedure to achieve signiﬁcant weight
loss, even in elderly patients [10]. BIB and Spatz balloon are the
most commonly used devices before surgery.
Spatz balloon has been introduced recently to overcome the
limitations of BIB, because the former has a longer intragastric life
of up to 12 months, can be adjusted with a system for inﬂation and
deﬂation, and has a safety mechanism that precludes its bowel
migration.
According to the medical literature, similarly to other studies in
elderly patients [11e15], no signiﬁcant difference was obtained
between the two procedures.6. Conclusion
The BIB and the Spatz ABS are effective in treating overweight
patients with BMI in the range of 27e30. The reported complica-
tions are the same. At present, there is only little information on the
safety of Spatz, and hence further studies regarding safety and
efﬁcacy of these intragastric devices are needed.
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